Patents Assigned to Green Cross Corporation
  • NOVEL C-ARYL ANSA SGLT2 INHIBITORS
    Publication number: 20140213642
    Abstract: Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.
    Type: Application
    Filed: June 14, 2012
    Publication date: July 31, 2014
    Applicant: GREEN CROSS CORPORATION
    Inventors: Min Ju Kim, Suk Ho Lee, Soongyu Choi
  • Arylpiperazine-containing purine derivatives and uses thereof
    Patent number: 8785453
    Abstract: A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: July 22, 2014
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Eun-Jung Park, Suk Youn Kang, Younggyu Kong, Junwon Lee, Hyun Jung Kim, Myung Eun Jung, Ki-Nam Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park
  • Method for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl) derivative and intermediate used therein
    Patent number: 8754210
    Abstract: Disclosed are: a method for preparing a 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}-methyl)thiophene-2-carboxamide derivative, which is a inhibitor of blood coagulation factor Xa, in a high purity and yield; and a novel intermedicate used therein.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: June 17, 2014
    Assignees: Green Cross Corporation, Legochem Bioscience Ltd.
    Inventors: Young Lag Cho, Sang Eun Chae, Seong Jin Kim, Ho Young Song, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim, Jinhwa Lee, Suk Ho Lee
  • Antibodies specifically binding to the epidermal growth factor receptor
    Patent number: 8748175
    Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: June 10, 2014
    Assignee: Green Cross Corporation
    Inventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
  • EPITOPE AND ITS USE OF HEPATITIS B VIRUS SURFACE ANTIGEN
    Publication number: 20140112923
    Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.
    Type: Application
    Filed: July 25, 2011
    Publication date: April 24, 2014
    Applicant: GREEN CROSS CORPORATION
    Inventors: Se-Ho Kim, Kwang-Won Hong, Yong-Won Shin, Ki Hwan Chang, Min-Soo Kim, Jung-Ae Im
  • NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS
    Publication number: 20140088079
    Abstract: The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.
    Type: Application
    Filed: June 1, 2012
    Publication date: March 27, 2014
    Applicant: GREEN CROSS CORPORATION
    Inventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon KIM, Dong Ho Hong, Misuk Kang
  • PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT OF LONICERA JAPONICA FOR PREVENTION AND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE
    Publication number: 20130310454
    Abstract: Disclosed is a composition for treating or preventing gastroesophageal reflux disease, which includes an organic solvent extract of Lonicerae Flos Thunberg. A fraction of the disclosed extract can be very effectively used for treating, preventing, or improving gastroesophageal reflux disease without side effects.
    Type: Application
    Filed: November 24, 2011
    Publication date: November 21, 2013
    Applicants: GREEN CROSS CORPORATION, GREEN CROSS HEALTH SCIENCE CO., LTD.
    Inventors: Young-Hyo Yoo, Jeom Yong Kim, Sun-Ok Kim, Joo Young Kim, Sun Kyu Park, Min Jung Jang
  • Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same
    Patent number: 8586550
    Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: November 19, 2013
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Jeongmin Kim, Suk Ho Lee, Junwon Lee, Kwang-Seop Song, Eun-Jung Park, Min Ju Kim, Hee Jeong Seo, Sung-Han Lee, Eun Jung Son, Jong Yup Kim, Suk Youn Kang, Younggyu Kong
  • C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same
    Patent number: 8541380
    Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: September 24, 2013
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Suk Ho Lee, Hee Jeong Seo, Min Ju Kim, Suk Youn Kang, Jeongmin Kim, Sung-Han Lee, Myung Eun Jung, Eun Jung Son, Kwang-Seop Song, Mi-Soon Kim
  • IDURONATE-2-SULFATASE AND USE THEREOF
    Publication number: 20130236442
    Abstract: Disclosed is a modified iduronate-2-sulfatase (IDS) gene constructed by inserting the nucleotide of SEQ ID NO: 2 into a wild-type IDS gene. In addition to being negatively charged, the improved IDS enzyme encoded by the modified gene exhibits a sufficient retention time in blood to target the bone, so that it is more effective for treating Hunter syndrome.
    Type: Application
    Filed: November 12, 2010
    Publication date: September 12, 2013
    Applicant: GREEN CROSS CORPORATION
    Inventors: Sy Lee, Sung-Ick Park
  • Method for preparing antigen effective for preventing anthrax infection
    Patent number: 8519108
    Abstract: The method of the present invention comprising successive column chromatography processes for the purification of an anthrax protective antigen can achieve an improved purity of the anthrax protective antigen product by effectively removing impurities (e.g., cellular residual proteins in the culture solution) without the loss of anthrax protective antigen. Therefore, the method of the present invention can be advantageously used for economically producing the anthrax protective antigen on a large scale.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: August 27, 2013
    Assignees: Korea Center For Disease Control and Prevention, Green Cross Corporation
    Inventors: Hee-Bok Oh, Bong-Su Kim, Gi-Eun Rhie, Jeong-Hoon Chun, Hun Kim, SinKoo Yeo, MahnHoon Park, Chong-Hwan Jonathan Chang, Mi Sun Ahn
  • (+)-3-HYDROXYMORPHINAN-BASED POLYCYCLE DERIVATIVES
    Publication number: 20130217672
    Abstract: A (+)-3-hydroxymorphinan-based polycycle derivative of formula (I) is effective as a neuroprotective agent for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and ischemic stroke.
    Type: Application
    Filed: May 13, 2011
    Publication date: August 22, 2013
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Jong Yup Kim, Jeongmin Kim, Kwang Woo Ahn
  • NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20130172278
    Abstract: The present invention relates to a novel compound with thiophene ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating metabolic disorders, particularly diabetes.
    Type: Application
    Filed: September 9, 2011
    Publication date: July 4, 2013
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Kwang-Seop Song, Suk Ho Lee
  • Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same
    Publication number: 20130090298
    Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
    Type: Application
    Filed: June 10, 2011
    Publication date: April 11, 2013
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Jeongmin Kim, Suk Ho Lee, Junwon Lee, Kwang-Seop Song, Eun-Jung Park, Min Ju Kim, Hee Jeong Seo, Sung-Han Lee, Eun Jung Son, Jong Yup Kim, Suk Youn Kang, Younggyu Kong
  • TUMOR-SPECIFIC PROMOTER AND ONCOLYTIC VIRUS VECTOR COMPRISING THE SAME
    Publication number: 20130065952
    Abstract: Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer.
    Type: Application
    Filed: April 26, 2010
    Publication date: March 14, 2013
    Applicants: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE, GREEN CROSS CORPORATION
    Inventors: Daekyung Koh, Seongtae Yun, Kyuhyun Lee, Hong-Kyu Lee, Mihee Hwang, Chae-Ok Yun, Eui-Cheol Jo
  • Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists
    Patent number: 8309584
    Abstract: A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: November 13, 2012
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Hee Jeong Seo, Min-Ah Kim, Jeongmin Kim, Sung-Han Lee, Myung Eun Jung, Mi-Soon Kim
  • HUMAN ANTIBODIES SPECIFICALLY BINDING TO THE HEPATITIS B VIRUS SURFACE ANTIGEN
    Publication number: 20120264921
    Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.
    Type: Application
    Filed: July 8, 2010
    Publication date: October 18, 2012
    Applicant: GREEN CROSS CORPORATION
    Inventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
  • ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF
    Publication number: 20120232090
    Abstract: A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.
    Type: Application
    Filed: November 5, 2010
    Publication date: September 13, 2012
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Eun-Jung Park, Suk Youn Kang, Younggyu Kong, Junwon Lee, Hyun Jung Kim, Myung Eun Jung, Ki-Nam Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park
  • ANTIBODIES SPECIFICALLY BINDING TO THE EPIDERMAL GROWTH FACTOR RECEPTOR
    Publication number: 20120231021
    Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.
    Type: Application
    Filed: November 2, 2009
    Publication date: September 13, 2012
    Applicant: GREEN CROSS CORPORATION
    Inventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo
  • METHOD FOR PREPARING 5-CHLORO-N-(METHYL)THIOPHEN-2-CARBOXAMIDE DERIVATIVE AND INTERMEDIATE USED THEREIN
    Publication number: 20120136149
    Abstract: Disclosed are: a method for preparing a 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}-methyl)thiophene-2-carboxamide derivative, which is a inhibitor of blood coagulation factor Xa, in a high purity and yield; and a novel intermedicate used therein.
    Type: Application
    Filed: July 7, 2010
    Publication date: May 31, 2012
    Applicants: LEGOCHEM BIOSCIENCE LTD., GREEN CROSS CORPORATION
    Inventors: Young Lag Cho, Sang Eun Chae, Seong Jin Kim, Ho Young Song, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim, Jinhwa Lee, Suk Ho Lee